Herein, we report the RNA hairpin loops from a 6-nucleotide hairpin library that bind 6′-acylated kanamycin A (1) and 6′-acylated neamine (2) identified by 2-Dimensional Combinatorial Screening (2DCS). Hairpins selected to bind 1 have K d 's ranging from 235-1035 nM, with an average K d of 618 nM. For 2, the selected hairpins bind with K d 's ranging from 135-2300 nM, with an average K d of 1010 nM. The selected RNA hairpin-ligand interactions are also specific for the ligand that they were selected to bind compared to the other arrayed ligand. For example, the mixture of hairpins selected for 1 on average bind 33-fold more tightly to 1 than 2 while the mixtures of hairpins selected for 2 on average bind 11-fold more tightly to 2 than 1. Secondary structure prediction of the selected sequences was completed to determine the motifs that each ligand binds, and the hairpin loop preferences for 1 and 2 were computed. For 1, the preferred hairpin loops contain an adenine separated by at least two nucleotides from a cytosine, for example ANNCNN (two-tailed p-value = 0.0010) and ANNNCN (two-tailed p-value <0.0001). For 2, the preferred hairpin loops contain both 5′GC and 5′CG steps (two-tailed p-value <0.0001). These results expand the information available on the RNA hairpin loops that bind small molecules and could prove useful for targeting RNA.RNA plays important roles in biological systems beyond the transfer of genetic material. For example, microRNAs regulate RNA lifetime and contribute to cancer,(1) riboswitches control gene expression by interacting with metabolites,(2) and viral RNAs facilitate translation of viral proteins (3). The most studied RNA therapeutic target for small molecules is the bacterial ribosome; most anti-bacterials that target the ribosome form direct contacts with RNA.(4) Other RNAs have been targeted with small molecules including HIV Trans-Activating Response (TAR) RNA (5) and Rev-Responsive Element (RRE) . Despite these studies, most RNA drug targets represent untapped potential.One difficulty in exploiting other RNA targets for small molecule therapeutics is the relatively limited information available about the small RNA motifs that small molecules bind. What is known about RNA-binding ligands has come from studying smaller motifs or domains derived from RNA therapeutic targets. Such approaches have helped develop compounds to inhibit HIV infection by targeting TAR RNA,(7) to inhibit bacterial growth by targeting the bacterial *Author to whom correspondence should be addressed; Email: E-mail: mddisney@buffalo.edu Phone: (716) (9,10) and to facilitate the elimination of plasmids that cause antibiotic resistance (11,12).To develop rational approaches to target RNA, information on the ligands that like to bind RNA and the RNA motifs that like to bind ligands is needed. The most commonly used methods to gather such information are systematic evolution of ligands by exponential enrichment (SELEX) and high throughput screening. In SELEX, RNAs that bind a ligand of interest with hig...